Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder

Massimiliano Buoli, Massimo Carlo Mauri, Alfredo Carlo Altamura

Research output: Contribution to journalArticlepeer-review


Introduction: Preliminary data indicate agomelatine as a promising molecule for both acute and long-term treatment of generalised anxiety disorder (GAD). Areas covered: The present review illustrates the pharmacokinetic properties of agomelatine and their implications for the management of GAD patients. A search of the main database sources (Medline, Isi Web of Knowledge and Medscape) was performed in order to obtain a complete and balanced evaluation of agomelatine pharmacokinetics for the treatment of GAD. The word 'agomelatine' was associated with 'pharmacokinetics', 'GAD', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles were included. Expert opinion: Short half-life and 1-day administration make agomelatine an interesting molecule for GAD treatment. However, potential interactions with a number of compounds necessitate caution when prescribing and using agomelatine in patients with psychiatric (e.g., alcohol abuse) or medical comorbidities. Further data are necessary to define a precise risk/benefit ratio in special populations such as elderly patients suffering from GAD.

Original languageEnglish
Pages (from-to)885-892
Number of pages8
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number6
Publication statusPublished - 2014


  • Agomelatine
  • Generalised anxiety disorder
  • Pharmacokinetics

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Medicine(all)


Dive into the research topics of 'Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder'. Together they form a unique fingerprint.

Cite this